期刊论文详细信息
Frontiers in Immunology | |
Corrigendum: The role of 18F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy | |
Immunology | |
Ruimin Wang1  Jiajin Liu1  Baixuan Xu1  Xiaodan Xu1  Guangyu Ma1  Jinming Zhang1  Xiaohui Luan2  Guanyun Wang3  Zhanbo Wang4  Wenwen Zhang5  Shichun Lu5  | |
[1] Department of Nuclear Medicine, The First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China;Department of Nuclear Medicine, The First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China;Graduate School, Medical School of Chinese People’s Liberation Army (PLA), Beijing, China;Department of Nuclear Medicine, The First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China;Nuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, Beijing, China;Department of Pathology, The First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China;Faculty of Hepato-Pancreato-Biliary Surgery, Chinese People’s Liberation Army (PLA) General Hospital/Institute of Hepatobiliary Surgery of Chinese People’s Liberation Army/Key Laboratory of Digital Hepetobiliary Surgery, People’s Liberation Army, Beijing, China; | |
关键词: unresectable hepatocellular carcinoma; conversion therapy; major pathological response; prognosis; F-FDG PET; | |
DOI : 10.3389/fimmu.2023.1219757 | |
received in 2023-05-09, accepted in 2023-05-12, 发布年份 2023 | |
来源: Frontiers | |
【 摘 要 】
【 授权许可】
Unknown
Copyright © 2023 Wang, Zhang, Luan, Wang, Liu, Xu, Zhang, Xu, Lu, Wang and Ma
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202310109124687ZK.pdf | 262KB | download |